explore -WSS

explore

author：explore 2025-09-28 02:28:09 - browse：4

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Sanofi strikes deal with Novavax, boosting the vaccine maker

hotspot

explore

WSS

Steward Health Care files for bankruptcy

HHS suspends federal funding for EcoHealth Alliance

H5N1 communication has been strictly for the birds

Obesity drug from Roche shows promise in early study

Obesity drug from Roche shows promise in early study

Medicare says breakthrough device reimbursement rule to come by summer

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Lilly’s weekly insulin works as well as daily products, new studies show

Virginia high school admissions case could be legal follow

Software glitch causes Tandem insulin pump to shutdown, FDA warns

New air purifier tech could be key to improving indoor air quality

Elevance, private equity launch primary care company

Walensky prepares to leave CDC — and Congress — behind

Supreme Court to hear if Covid misinformation is protected speech

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

After gene therapy, two congenitally deaf children hear for the first time

focus

First recipient of genetically engineered pig kidney has died

Telehealth startups turn to complex chronic diseases

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Hottest summer in 2,000 years puts focus on extreme heat, health

H5N1 communication has been strictly for the birds

Google says AlphaFold 3 can map a vast universe of biomolecules

explore

hotspot

explore

focus